Communications and Marketing

New vaccine strategy against Epstein Barr virus

No. 02 | 08/01/2019 | by Rei

The Epstein Barr viruses (EBV) are very common and in most cases, an infection causes no harm. However, sometimes the outcome is a serious disease. There is no effective immunization protection against EBV so far, because the pathogen is very difficult to get hold of. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now developed a new strategy for developing a vaccine against EBV that will simultaneously prepare the immune system for different stages of the pathogen. In this way, the researchers are convinced to have made major progress towards developing a vaccine against EBV.

Epstein Barr viruses in blood vessels
© Adobe Stock/DKFZ

More than 90 percent of the world population is infected with Epstein-Barr virus (EBV) – usually completely unnoticed. The virus is well adapted to the human body and the immune system keeps the virus well in check. Nevertheless, EBV is anything but harmless. Besides infectious mononucleosis (Pfeiffer's disease), the virus can also cause cancer. In addition, it is suspected to promote autoimmune diseases such as multiple sclerosis.

"We therefore urgently need a vaccine against EBV," said Henri-Jacques Delecluse from the German Cancer Research Center (DKFZ). In collaboration with partners from the Munich Helmholtz Center and Heidelberg University, the research team led by Delecluse has now developed a new strategy for developing a vaccine which they hope will bring a breakthrough.

The central problem in developing a protective vaccination against EBV is that the virus goes through various phases throughout its life cycle. Directly after infection, it usually remains in a latent phase where it appears to remain silent in infected B cells of the immune system, replicating together with the B cells when they divide. However, this latent phase is anything but harmless because diseases such as lymphoma can arise at this stage. When the virus reactivates from the latent phase, it progresses into the so-called lytic phase where new viral particles form and are released. EBV produces very different repertoires of viral proteins in the two phases.

"Previous attempts to develop a vaccine mostly targeted a particular protein from the capsid," explains Delecluse. "However, this means that the vaccine prepares the immune system only for EBV in its lytic phase." An immune response that targets the capsid protein can only be successful if free virus particles are present in the body. Study participants who were given this type of vaccine were not protected from later infection with EBV. Vaccine attempts that were directed exclusively against proteins of the latent phase were equally unsuccessful.

"We know that the immune response in healthy EBV-infected people is directed against proteins of both lifecycle phases," said Delecluse. "Therefore, it was obvious that we should develop a vaccine which takes this into account and also contains antigens from both phases." The basis for this vaccine are virus-like particles (VLPs), which were also used in previously developed vaccines. VLPs are empty virus shells that do not contain viral genetic material and against which the body can mount an immune response. A new approach taken by the scientists led by DKFZ's Delecluse was to additionally equip the VLPs with proteins of the latent phase.

The investigators tested whether these particles were in fact capable of causing a protective effect in experiments with mice whose bone marrow had been replaced by human bone marrow. As a result, the rodents are equipped with a predominantly human immune system. When the researchers injected these animals with the VLPs loaded with two types of antigen groups, the mice developed a specific immune response with participation also of T cells, which are essential for successful defense. In addition, the animals were protected from infection with EBV.

"We have demonstrated that this approach principally works for developing an EBV vaccine," Delecluse says. He adds that in a next step, this prototype EBV vaccine must be further developed and, step by step, examined for possible use in humans.

Dwain G. van Zyl, Ming-Han Tsai, Anatoliy Shumilov, Viktor Schneidt, Rémy Poirey, Bettina Schlehe, Herbert Fluhr, Josef Mautner und Henri-Jacques Delecluse (2018): Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLOS Pathogens 2018, DOI: 10.1371/journal.ppat.1007464

A picture is available for Download:
www.dkfz.de/de/presse/pressemitteilungen/2019/bilder/AdobeStock_223522492_Epstein-Barr-Virus.jpg 
Caption: Epstein Barr viruses in blood vessels

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Adobe Stock/DKFZ".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS